Skip to Content

Zanubrutinib Side Effects

Medically reviewed by Drugs.com. Last updated on Nov 7, 2020.

For the Consumer

Applies to zanubrutinib: oral capsule

Side effects requiring immediate medical attention

Along with its needed effects, zanubrutinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking zanubrutinib:

More common

  • Black, tarry stools
  • bladder pain
  • bleeding gums
  • bloody or cloudy urine
  • blurred vision
  • body aches or pain
  • chest pain or tightness
  • chills
  • cough
  • coughing up blood
  • decreased urine
  • difficult, burning, or painful urination
  • difficulty in breathing or swallowing
  • dizziness
  • dry mouth
  • ear congestion
  • fast, slow, or irregular heartbeat
  • fever
  • frequent urge to urinate
  • headache
  • increased menstrual flow or vaginal bleeding
  • increased thirst
  • loss of appetite
  • loss of voice
  • lower back or side pain
  • mood changes
  • muscle pain or cramps
  • nausea or vomiting
  • nervousness
  • nosebleeds
  • numbness or tingling in the hands, feet, or lips
  • painful or difficult urination
  • pale skin
  • paralysis
  • pinpoint red spots on the skin
  • pounding in the ears
  • prolonged bleeding from cuts
  • runny or stuffy nose
  • seizures
  • sneezing
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • swollen glands
  • unusual bleeding or bruising
  • unusual tiredness or weakness

Side effects not requiring immediate medical attention

Some side effects of zanubrutinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to zanubrutinib: oral capsule

Hematologic

Very common (10% or more): Hemorrhage (50%), all grades neutropenia (38%), Grade 3 or 4 neutropenia (15%), all grades thrombocytopenia (27%), Grade 3 or 4 thrombocytopenia (10%), all grades leukopenia (25%), all grades anemia (14%)

Common (1% to 10%): Grade 3 or 4 anemia, Grade 3 or 4 leukopenia[Ref]

Immunologic

Very common (10% or more): Grade 3 or higher infection (23%)[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (e.g., musculoskeletal pain, musculoskeletal discomfort, myalgia, back pain, arthralgia, arthritis) (14%)[Ref]

Metabolic

Very common (10% or more): Blood uric acid increased (29%), hypokalemia (14%)

Genitourinary

Very common (10% or more): Urinary tract infection (11%)[Ref]

Hepatic

Very common (10% or more): ALT increased (28%), bilirubin increased (24%)[Ref]

Oncologic

Common (1% to 10%): Second primary malignancies (e.g., nonskin carcinoma)[Ref]

Respiratory

Very common (10% or more): Upper respiratory tract infection (39%), pneumonia (15%), cough (14%)[Ref]

Cardiovascular

Very common (10% or more): Hypertension (12%)

Common (1% to 10%): Atrial fibrillation, atrial flutter[Ref]

Dermatologic

Very common (10% or more): Rash (36%), bruising (14%)[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (23%), constipation (13%)[Ref]

References

1. "Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc, San Mateo, CA.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.